You are here:

telbivudine (Sebivo)

Advice

Following a full submission

telbivudine (Sebivo®) is accepted for use within NHS Scotland for the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, persistently elevated serum alanine aminotransferase levels and histological evidence of active inflammation and/or fibrosis.

For a number of therapeutic endpoints telbivudine proved to be equivalent or superior to a comparator nucleoside reverse transcriptase inhibitor.

Drug Details

Drug Name: telbivudine (Sebivo)
SMC Drug ID: 438/08
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: For the treatment of chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replications
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Accepted
Date Advice Published: 11 February 2008

Back